Significant biosimilar activities this week include:

  • 23 April 2020: Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02.

  • 28 April 2020: Mylan and Biocon launched Fulphila® (pegfilgrastim) in Canada. Ful...

29 Apr 20 | All | Gedeon Richter, Mycenax | Gedeon Richter announces it has entered an asset purchase agreement with Mycenax Biotech for the purchase of a biosimilar tocilizumab product. Under the agreement, Richter will receive worldwide rights to develop, manufacture...

Significant biosimilar activities this week include:

  • On 02 March 2020, Celltrion launched Remsima SC, its subcutaneous infliximab product, in the UK. To support the launch, Celltrion held a symposium at which it showcased the product and supporting data. Celltr...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags